Immunic to Participate in Investor Conferences in March

Rhea-AI Summary

Immunic (Nasdaq: IMUX) will attend investor conferences in March 2026, presenting leadership panels and offering one-on-one investor meetings.

Executives Daniel Vitt, Ph.D., Jason Tardio and Jessica Breu will appear at the Leerink Partners Global Healthcare Conference (March 8–11) and the Stifel 2026 Virtual CNS Forum (March 17–18). Webcasts will be available on the company's Events and Presentations page.

NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March:

• March 8-11: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jason Tardio, President and Chief Operating Officer of Immunic, will participate in a fireside chat on Wednesday, March 11, at 10:40 am ET at this conference in Miami. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.

Dr. Vitt, Mr. Tardio and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or Jessica Breu at: jessica.breu@imux.com.

• March 17-18: Stifel 2026 Virtual CNS Forum. Dr. Vitt and Mr. Tardio will participate in a fireside chat on Wednesday, March 18, at 4:00 pm ET at this virtual conference. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.

Dr. Vitt, Mr. Tardio and Mrs. Breu will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Stifel representative or Jessica Breu at: jessica.breu@imux.com.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases such as celiac disease, inflammatory bowel disease, and Graft-versus-Host-Disease. IMU-381 comprises next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases leveraging the company's Nurr1 platform. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-conferences-in-march-302702020.html

SOURCE Immunic, Inc.

FAQ

When will Immunic (IMUX) present at the Leerink Partners Global Healthcare Conference in March 2026?

Immunic will present a fireside chat on March 11, 2026 at 10:40 am ET. According to the company, Daniel Vitt and Jason Tardio will speak and webcasts will be available on the company's Events and Presentations page, with one-on-one meetings also offered.

How can investors watch Immunic's (IMUX) webcasts from the March 2026 conferences?

Investors can view webcasts via the company's Events and Presentations page on its investor site. According to the company, both the Leerink fireside chat and the Stifel virtual session will be webcast and posted at https://ir.imux.com/events-and-presentations.

Who from Immunic (IMUX) will participate in investor meetings at the March 2026 conferences?

Daniel Vitt, Jason Tardio and Jessica Breu will attend one-on-one investor meetings at both conferences. According to the company, investors should contact their conference representative or Jessica Breu at jessica.breu@imux.com to schedule meetings.

When is Immunic's (IMUX) fireside chat at the Stifel 2026 Virtual CNS Forum in March 2026?

Immunic's fireside chat at Stifel is scheduled for March 18, 2026 at 4:00 pm ET. According to the company, the session will be virtual, led by Daniel Vitt and Jason Tardio, and will be available as a webcast on the investor site.

What topics will Immunic (IMUX) executives cover in the March 2026 conference presentations?

The announcement states executives will participate in fireside chats and investor meetings covering company developments and strategy. According to the company, the sessions are intended to inform investors and will be accessible via webcast and one-on-one meetings at the conferences.

How can investors request a one-on-one meeting with Immunic (IMUX) at the March 2026 conferences?

To request a meeting, investors should contact their conference representative or email jessica.breu@imux.com. According to the company, Jessica Breu is coordinating one-on-one investor meetings for both the Leerink and Stifel events.